ClinicalTrials.Veeva

Menu
R

Rare Disease Research, LLC | Atlanta, GA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

EDG-5506
GTX-102
Risdiplam
Ecopipam
Ataluren
Galcanezumab
Vesleteplirsen
Edasalonexent
WVE-210201
Pamrevlumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

36 of 67 total trials
Status recently updated

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy (FSHD)

The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female ad...

Enrolling
Begins enrollment this month
Facioscapulohumeral Muscular Dystrophy
Biological: EPI-321

PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral z...

Enrolling
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Drug: zagociguat 15mg
Drug: Placebo

HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a ce...

Active, not recruiting
Genetic Diseases, X-Linked
Muscular Diseases
Biological: Deramiocel (CAP-1002)
Biological: Placebo

The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy includ...

Active, not recruiting
Duchenne Muscular Dystrophy
Drug: Sevasemten Dose 2
Drug: Sevasemten Dose 4

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

The main aim of the study is to determine if SHP611 given by injection into the spinal fluid that surrounds the brain and spinal cord (intrathecal; I...

Active, not recruiting
Metachromatic Leukodystrophy (MLD)
Drug: SHP611

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant i...

Enrolling
Prader-Willi Syndrome
Other: Placebo tablet
Drug: Pitolisant tablet

The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment.Participants will re...

Active, not recruiting
Dravet Syndrome (DS)
Epilepsy
Drug: Soticlestat

The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondropl...

Enrolling
Achondroplasia
Drug: TYRA-300 0.375 mg/kg
Drug: TYRA-300 0.125 mg/kg

Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in appr...

Active, not recruiting
Muscular Dystrophy, Duchenne
Drug: Eteplirsen

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[...

Enrolling
Tourette Syndrome
Drug: Ecopipam

This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of...

Active, not recruiting
Neuromuscular Diseases
SMA
Drug: Placebo
Drug: taldefgrobep alfa

The primary objective of this study is to evaluate the safety and tolerability of a single dose of INS1201 via IT administration in ambulatory male p...

Enrolling
Duchenne Muscular Dystrophy
Genetic: INS1201
Status recently updated

In this study, researchers will learn more about the use of a higher dose of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA)....

Enrolling
Active, not recruiting
Spinal Muscular Atrophy
Drug: Nusinersen

This is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult...

Enrolling
Phenylketonurias
Genetic: NGGT002

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN00...

Enrolling
Fragile X Syndrome
Drug: Placebo
Drug: ZYN002 - transdermal gel

The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of singl...

Enrolling
Phenylketonuria
Drug: Placebo Tablet
Drug: JNT-517 Suspension

The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)

Invitation-only
Angelman Syndrome
Drug: GTX-102

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

Trial sponsors

Edgewise Therapeutics logo
E
Sarepta Therapeutics logo
Ultragenyx logo
PTC Therapeutics logo
AbbVie logo
A
C
FibroGen logo
Genentech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems